U.S. Clears GlaxoSmithKline Drug For Preventing Influenza

WASHINGTON (Reuters) - GlaxoSmithKline Plc's prescription flu treatment Relenza has won U.S. approval for preventing influenza in adults and children ages 5 and older, regulators said on Wednesday.

Back to news